Izlaganje sa skupa

MAGNESIUM AND KETAMINE IN THE TREATMENT OF DEPRESSION

Natalia Górska ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Jakub Słupski ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Łukasz P. Szałach ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Adam Włodarczyk ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Joanna Szarmach ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Katarzyna Jakuszkowiak-Wojten ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Maria Gałuszko-Węgielnik ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Alina Wilkowska ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Mariusz Stanisław Wiglusz ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Wiesław Jerzy Cubała ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

Sažetak

Depression affects over 121 million people annually worldwide. Relatively low remission rates among depressive patients
enforce the search for new therapeutic solutions and an urgent need to develop faster-acting antidepressants with a different
mechanism of action occurs. The pathomechanism of depression postulated by the monoamine hypothesis is limited. The results of
abnormalities in glutamate and γ-aminobutyric acid (GABA) systems in the brains of people with mood disorders allowed to develop
new theories regarding pathophysiology of these disorders. Glutamatergic transmission is influenced by magnesium and ketamine
through glutamatergic N-methyl-D-aspartate receptor (NMDAR) antagonistic effects.
Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR
subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic
elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus. Combination of ketamine and
magnesium in a normal magnesium level presents a superadditive effect in depression treatment. Analysed substances affect the
GABAergic system and have anti-inflammatory effects, which is correlated with their antidepressant effect.
The synergistic interaction between the pharmacodynamic activity of magnesium and ketamine may be of particular importance
for patients with mood disorders. Further research is needed to determine the relationship between magnesium levels and ketamine
treatment response mainly in the attempt to establish if the magnesium supplementation can change ketamine treatment response
time or present superadditive effect.

Ključne riječi

magnesium; ketamine; depression

Hrčak ID:

264171

URI

https://hrcak.srce.hr/264171

Datum izdavanja:

4.9.2019.

Posjeta: 484 *